SER (Serina Therapeutics) Total Liabilities: $9.67 Mil (As of Mar. 2026)


SER Serina Therapeutics Inc SER
12 GF Score
Price $1.97
! 1 Warning Sign
View Full Analysis

What is Serina Therapeutics Total Liabilities?

Serina Therapeutics SER +8.84% 12 Total Liabilities is $9.67 Mil as of Mar. 2026. GuruFocus rates SER with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Serina Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $9.67 Mil.

Serina Therapeutics's quarterly Total Liabilities declined from Sep. 2025 ($10.82 Mil) to Dec. 2025 ($6.99 Mil) but then increased from Dec. 2025 ($6.99 Mil) to Mar. 2026 ($9.67 Mil).

Serina Therapeutics's annual Total Liabilities declined from Dec. 2023 ($41.26 Mil) to Dec. 2024 ($6.22 Mil) but then increased from Dec. 2024 ($6.22 Mil) to Dec. 2025 ($6.99 Mil).

Serina Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Serina Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Serina Therapeutics Total Liabilities Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
36.95 38.64 41.26 6.22 6.99

Serina Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.17 7.30 10.82 6.99 9.67
SER
12GF Score
Serina Therapeutics Inc SER
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Serina Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Serina Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.563+(3.142+0.283
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=6.99

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=6.951--0.037
=6.99

Serina Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=6.34+(3.169+0.162
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=9.67

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=27.299-17.628
=9.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $9.67 Mil mean?
Serina Therapeutics (SER) has a Total Liabilities of $9.67 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Serina Therapeutics and its competitors.
Is Serina Therapeutics' Total Liabilities too high?
Serina Therapeutics' current Total Liabilities is $9.67 Mil. Overall, Serina Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Serina Therapeutics' Total Liabilities compare to NRSN and IGC?
Serina Therapeutics' Total Liabilities of $9.67 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Serina Therapeutics and its competitors. Serina Therapeutics's current Total Liabilities is $9.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Serina Therapeutics stock overvalued right now?
Serina Therapeutics (SER) has a current Total Liabilities of $9.67 Mil. The current Total Liabilities is $9.67 Mil. Serina Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Serina Therapeutics (SER), the current Total Liabilities is $9.67 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Serina Therapeutics Business Description

Other Exchanges 2BO:Germany
Address 601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
12GF Score

Get the complete analysis for SER

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.97
Price